Romiplostim in chronic immune thrombocytopenic purpura

Clinical Therapeutics

Volumn 31, Issue 9, 2009, Pages 1887-1907

  Cersosimo, Robert J ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

immune (idiopathic) thrombocytopenic purpura; ITP; Nplate; romiplostim

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; IMMUNOGLOBULIN; IMMUNOGLOBULIN D ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN; VINCA ALKALOID;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; BLINDNESS; BONE MARROW; BONE PAIN; BREAST TUMOR; CHRONIC DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTUSION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ECCHYMOSIS; EPISTAXIS; ESCHERICHIA COLI; FATIGUE; GINGIVA BLEEDING; HEADACHE; HEART INFARCTION; HEMATOMA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE BLEEDING; INJECTION SITE IRRITATION; INSOMNIA; LOOSE FECES; MENORRHAGIA; MIGRAINE; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NECK PAIN; ORAL BLEEDING; ORAL BLISTER; PAPILLEDEMA; PERIPHERAL EDEMA; QUALITY OF LIFE; RECOMBINANT DNA TECHNOLOGY; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; SPLENECTOMY; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOPHLEBITIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; VAGINA BLEEDING;

ANIMALS; BLOOD PLATELETS; CHRONIC DISEASE; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 72149133382     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.09.013     Document Type: Article

References (60)

1. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 113 (2009) 2386-2393
2. Stasi R., Evangelista M.L., Stipa E., et al. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost. 99 (2008) 4-13
3. Dickerhoff R., and von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr. 137 (2000) 629-632
4. Kühne T., Imbach P., Bolton-Maggs P.H., et al., Intercontinental Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: An observational study. Lancet. 358 (2001) 2122-2125
5. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 88 (1996) 3-40
6. Frederiksen H., and Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 94 (1999) 909-913
7. Neylon A.J., Saunders P.W., Howard M.R., et al., Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a populationbased cohort of 245 patients. Br J Haematol. 122 (2003) 966-974
8. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 120 (2003) 574-596
9. Terrell D.R., Johnson K.K., Vesely S.K., and George J.N. Is immune thrombocytopenic purpura less common among black Americans?. Blood. 105 (2005) 1368-1369
10. Landgren O., Gridley G., Fears T.R., and Caporaso N. Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and White veterans. Blood. 108 (2006) 1111-1112
11. Stasi R., Stipa E., Masi M., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 98 (1995) 436-442
12. van Leeuwen E.F., van der Ven J.T., Engelfriet C.P., and von dem Borne A.E. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood. 59 (1982) 23-26
13. McMillan R., Wang L., and Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost. 1 (2003) 485-491
14. Cines D.B., and Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med. 346 (2002) 995-1008
15. Cooper N., and Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 133 (2006) 364-374
16. Brighton T.A., Evans S., Castaldi P.A., et al. Prospective evaluation of the clinical usefulness of an antigenspecific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 88 (1996) 194-201
17. Kuwana M., Kaburaki J., and Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 102 (1998) 1393-1402
18. Olsson B., Andersson P.O., Jernås M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 9 (2003) 1123-1124
19. Stevens W., Koene H., Zwaginga J.J., and Vreugdenhil G. Chronic idiopathic thrombocytopenic purpura: Present strategy, guidelines and new insights. Neth J Med. 64 (2006) 356-363
20. Stasi R., and Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 79 (2004) 504-522
21. George J.N., el-Harake M.A., and Raskob G.E. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 331 (1994) 1207-1211
22. George J.N. Idiopathic thrombocytopenic purpura in adults: Current issues for pathogenesis, diagnosis and management. Hematol J. 5 Suppl 3 (2004) S12-S14
23. Blanchette V., Freedman J., and Garvey B. Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol. 35 Suppl 1 (1998) 36-51
24. Godeau B., Lesage S., Divine M., et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood. 82 (1993) 1415-1421
25. Bussel J.B., and Pham L.C. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: Review of the literature. Vox Sang. 52 (1987) 206-211
26. Godeau B., Chevret S., Varet B., et al., French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial. Lancet. 359 (2002) 23-29
27. Bussel J.B., Graziano J.N., Kimberly R.P., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect. Blood. 77 (1991) 1884-1893
28. Scaradavou A., Woo B., Woloski B.M., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood. 89 (1997) 2689-2700
29. Newman G.C., Novoa M.V., Fodero E.M., et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 112 (2001) 1076-1078
30. Kojouri K., Vesely S.K., Terrell D.R., and George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 104 (2004) 2623-2634
31. Burzynski J. New options after firstline therapy for chronic immune thrombocytopenic purpura. Am J Health Syst Pharm. 66 Suppl 2 (2009) S11-S21
32. Vesely S.K., Perdue J.J., Rizvi M.A., et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: A systematic review. Ann Intern Med. 140 (2004) 112-120
33. Nplate (romiplostim) [prescribing information] (2008), Amgen Inc, Thousand Oaks, Calif. http://www.nplate.com/patient/pdf/nplate_pi.pdf Accessed August 17, 2009
34. Wang B., Nichol J.L., and Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 76 (2004) 628-638
35. Kumagai Y., Fujita T., Ozaki M., et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: A randomized, placebo-controlled study. J Clin Pharmacol. 47 (2007) 1489-1497
36. Newland A., Caulier M.T., Kappers-Klunne M., et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 135 (2006) 547-553
37. Bussel J.B., Kuter D.J., George J.N., et al. AMG 531, a thrombopoiesisstimulating protein, for chronic ITP [published correction appears in N Engl J Med. 2006;355:2054]. N Engl J Med. 355 (2006) 1672-1681
38. Nichol J.L. The Mpl ligand and platelet homeostasis. Acta Paediatr Suppl. 424 (1998) 7-15
39. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet. 371 (2008) 395-403
40. FDA advisory committee briefing document: Oncologic Drugs Advisory Committee March 12, 2008. Biological License Application (BLA) 125268: Romiplostim for the treatment of thrombocytopenia in certain adult patients with chronic immune (idiopathic) thrombocytopenia purpura. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b1-01-FDA.pdf Accessed June 3, 2009
41. Bussel J.B., Kuter D.J., Pullarkat V., et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP [published correction appears in Blood. 2009;113:4822]. Blood. 113 (2009) 2161-2171
42. US Food and Drug Administration pregnancy risk categories. Drugs in pregnancy. http://www.safefetus.com/fda_category.asp Accessed August 21, 2009
43. Kantarjian H., Fenaux P., Sekeres M.A., et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): Update including extended treatment. Blood (ASH Annual Meeting Abstracts) 110 (2007) Abstract 250
44. US Food and Drug Administration (FDA). FDA approves first bone marrow stimulator to treat immunerelated low platelet counts. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01876.html Accessed February 24, 2009
45. Jawa V., Hokom M., Hu J., et al. Low immunogenicity to romiplostim in clinical studies with ITP subjects. Blood (ASH Annual Meeting Abstracts) 112 (2008) Abstract 3425
46. Kuter D.J., Mufti G., Bain B., et al. Evaluation of bone marrow reticulin formation in romiplostim-treated adult patients with chronic immune thrombocytopenic purpura (ITP). Blood (ASH Annual Meeting Abstracts) 112 (2008) Abstract 3416
47. Beckman E., and Brown Jr. A.W. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med. 114 (1990) 1241-1243
48. Mufti G., Bagg A., Hasserjian R., et al. Bone marrow reticulin in patients with immune thrombocytopenic purpura. J Support Oncology. 5 Suppl 2 (2007) 80-81
49. Liebman H., Henry D., Lefrere F., et al. Long-term safety profile of romiplostim in patients with chronic immune thrombocytopenia (ITP). Blood (ASH Annual Meeting Abstracts) 112 (2008) Abstract 3415
50. Nplate (romiplostim). The Nplate Network of Experts Understanding and Supporting Nplate and Patients (NEXUS) Program. www.nplatenexus.com Accessed August 17, 2009
51. George J., Bussel J.B., Lyons R.M., et al. Self-injection of romiplostim by patients with chronic immune thrombocytopenic purpura (ITP). Blood (ASH Annual Meeting Abstracts) 112 (2008) Abstract 4707
52. Newton M. Romiplostim: The risk evaluation and mitigation strategy (REMS). Comm Oncol. 5 (2008) 654-656
53. Nplate (romiplostim) reimbursement. http://www.ext.amgen.com/reimbursement_connection/nplate_romiplostim.html Accessed August 12, 2009
54. George J.N., Mathias S.D., Go R.S., et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: Results of two randomized, placebo-controlled trials. Br J Haematol. 144 (2009) 409-415
55. Nplate (romiplostim) [product information]. nplatenexus.com Accessed August 17, 2009
56. Tiu R.V., and Sekeres M.A. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. Expert Opin Biol Ther. 8 (2008) 1021-1030
57. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: Current status of thrombopoietic agents. Semin Hematol. 46 Suppl 2 (2009) S26-S32
58. Vadhan-Raj S., Verschraegen C.F., Bueso-Ramos C., et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 132 (2000) 364-368
59. Pullarkat V. Finding a place for thrombopoietin receptor agonists in the treatment of chronic ITP. Comm Oncol. 5 (2008) 653-654
60. Rodeghiero F., and Ruggeri M. Chronic immune thrombocytopenic purpura. New agents. Hamostaseologie. 29 (2009) 76-79